News & Updates
Filter by Specialty:
Entinostat-exemestane combo yields survival benefit for HR+ advanced BC
In women with hormone-receptor positive advanced breast cancer (HR+ aBC), the addition of the class I selective histone deacetylase (HDAC) inhibitor entinostat to exemestane appeared to be better than treatment with exemestane alone in terms of survival benefit, according to a phase III trial from China.
Entinostat-exemestane combo yields survival benefit for HR+ advanced BC
04 Jan 2022
Breast cancer survivors at greater risk of non-Hodgkin lymphoma
Non-Hodgkin lymphoma (NHL), particularly follicular and mature T/NK-cell lymphomas, is more likely to develop among patients with breast cancer, a recent study has found. Moreover, such risk is greater among those who had been treated with hormone therapy.
Breast cancer survivors at greater risk of non-Hodgkin lymphoma
03 Jan 2022
First chronic obstructive pulmonary disease exacerbation predicts risk of more
Exacerbation history, along with the presence of severe dyspnoea and maintenance treatment use, is associated with an increased risk of future exacerbation episodes in patients with chronic obstructive pulmonary disease, a study has found.